基线血清前列腺特异性抗原值可预测后续前列腺癌死亡风险——来自挪威前列腺癌联盟的研究结果
挪威前列腺癌联盟基于176 099名40岁及以上、基线PSA<4.0 ng/ml且无前列腺癌诊断的男性,评估16年前列腺癌死亡风险。基线PSA水平与前列腺癌死亡率相关(两个年龄组C指数均为0.72),84%男性基线PSA<2.0 ng/ml,1346例死亡中712例(53%)发生在基线PSA 2.0-3.9 ng/ml的16%男性中。
要点
- 基线PSA<4.0 ng/ml的40-69岁男性中,PSA水平可分层未来15-20年前列腺癌死亡风险。
- 基线PSA 2.0-3.9 ng/ml的16%男性贡献了53%(712/1346)的前列腺癌死亡。
- 两个年龄组(40-54岁和55-69岁)的C指数均为0.72。
核心结论
- 研究重复了既往研究结果,即40-69岁男性的基线PSA可用于分层未来15-20年前列腺癌死亡风险。
主要发现
- 未患前列腺癌男性的中位随访时间为17.9年。
- 总体84%的男性基线PSA<2.0 ng/ml,1346例死于前列腺癌,其中712例(53%)死亡发生在基线PSA 2.0-3.9 ng/ml的16%男性中。
- 基线PSA水平与前列腺癌死亡率相关,40-54岁和55-69岁两个年龄组的C指数均为0.72。
关键数值与推荐
- 基线PSA分层为<0.5、0.5-0.9、1.0-1.9、2.0-2.9和3.0-3.9 ng/ml,与后续前列腺癌死亡的相关性C指数在两个年龄组均为0.72。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出任何特定PSA测量的原因仍未知,这代表一项局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA) levels in midlife are strongly associated with the long-term risk of lethal prostate cancer in cohorts not subject to screening. This is the first study evaluating the association between PSA levels drawn as part of routine medical care in the Norwegian population and prostate cancer incidence and mortality. The objective of the study was to determine the association between midlife PSA levels <4.0 ng/ml, drawn aspart of routine medical care, and long-term risk of prostate cancer death. METHODS: The Norwegian Prostate Cancer Consortium collected >8 million PSA results from >1 million Norwegian males (more than or equal to) 40 yr of age. We studied 176 099 men (predefined age strata: 40-54 and 55-69 yr) without a prior prostate cancer diagnosis who had a nonelevated baseline PSA level (<4.0 ng/ml) between January 1,1995 and December 31, 2005. We assessed the 16-yr risk of prostate cancer mortality. We calculated the discrimination (C-index) between predefined PSA strata (<0.5, 0.5-0.9, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml) and subsequent prostate cancer death. Survival curves were plotted using the Kaplan-Meier method. KEY FINDINGS AND LIMITATIONS: The median follow-up time of men who did not get prostate cancer was 17.9 yr. Overall, 84% of men had a baseline PSA level of <2.0 ng/ml and 1346 men died from prostate cancer, with 712 deaths (53%) occurring in the 16% of men with the highest baseline PSA of 2.0-3.9 ng/ml. Baseline PSA levels were associated with prostate cancer mortality (C-index 0.72 for both age groups, 40-54 and 55-69 yr). The fact that the reason for any given PSA measurement remains unknown represents a limitation. CONCLUSIONS AND CLINICAL IMPLICATIONS: We replicated prior studies that baseline PSA at age 40-69 yr can be used to stratify a man's risk of dying from prostate cancer within the next 15-20 yr. PATIENT SUMMARY: A prostate-specific antigen level obtained as part of routine medical care is strongly associated with a man's risk of dying from prostate cancer in the next two decades.
引用
- Bjerner J, Bratt O, Aas K, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2023. PMID: 37169639. doi:10.1016/j.eururo.2023.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。